{"protocolSection":{"identificationModule":{"nctId":"NCT00082381","orgStudyIdInfo":{"id":"H8O-MC-GWAA"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","officialTitle":"Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin"},"statusModule":{"statusVerifiedDate":"2015-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-06"},"primaryCompletionDateStruct":{"date":"2008-07","type":"ACTUAL"},"completionDateStruct":{"date":"2008-07","type":"ACTUAL"},"studyFirstSubmitDate":"2004-05-06","studyFirstSubmitQcDate":"2004-05-10","studyFirstPostDateStruct":{"date":"2004-05-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-07-16","resultsFirstSubmitQcDate":"2013-06-25","resultsFirstPostDateStruct":{"date":"2013-07-31","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-03-19","lastUpdatePostDateStruct":{"date":"2015-04-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"},"collaborators":[{"name":"Eli Lilly and Company","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c)."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"],"keywords":["Diabetes","Insulin glargine","comparator","Amylin","Lilly"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":551,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Exenatide Arm","type":"EXPERIMENTAL","description":"exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks","interventionNames":["Drug: Exenatide (AC2993)"]},{"label":"Insulin Glargine Arm","type":"ACTIVE_COMPARATOR","description":"subcutaneous injection, once daily; forced titration to target blood glucose level","interventionNames":["Drug: Insulin glargine"]}],"interventions":[{"type":"DRUG","name":"Exenatide (AC2993)","description":"subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks","armGroupLabels":["Exenatide Arm"],"otherNames":["Byetta"]},{"type":"DRUG","name":"Insulin glargine","description":"subcutaneous injection, once daily; forced titration to target blood glucose level","armGroupLabels":["Insulin Glargine Arm"],"otherNames":["Lantus"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Glycosylated Hemoglobin (HbA1c)","description":"Change in HbA1c from baseline to week 26","timeFrame":"Baseline, week 26"}],"secondaryOutcomes":[{"measure":"Percentage of Patients Achieving HbA1c <=7%","description":"Percentage of patients in each arm who had HbA1c \\>7% at baseline and had HbA1c \\<=7% at week 26 (percentage = \\[number of subjects with HbA1c \\<=7% at week 26 divided by number of subjects with HbA1c \\>7% at baseline\\] \\* 100%).","timeFrame":"26 weeks"},{"measure":"Change in Body Weight","description":"Change in body weight from baseline to week 26","timeFrame":"Baseline, week 26"},{"measure":"Change in Fasting Serum Glucose","description":"Change in fasting serum glucose from baseline to week 26","timeFrame":"Baseline, week 26"},{"measure":"Change in 7-point Self-monitored Blood Glucose (SMBG) Profile","description":"Change in 7-point (pre-breakfast, 2 hour post breakfast, pre-lunch, 2 hour post lunch, pre-dinner, 2 hour post dinner, 0300 hours) SMBG profile from baseline to week 26","timeFrame":"Baseline, week 26"},{"measure":"Percentage of Patients With Hypoglycemic Events","description":"Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study divided by the total number of patients who participated in the 26 week Parent Study","timeFrame":"26 weeks"},{"measure":"Change in Rate of Hypoglycemic Events","description":"Change in rate of hypoglycemic events per 30 days per patient from baseline to week 26","timeFrame":"Baseline, week 26"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients have been treated with a stable dose of one of the following for at least 3 months prior to screening: 1. 1500 to 2550 mg/day immediate-release metformin (or 1500 to 2000 mg/day extended-release metformin) and at least an optimally effective dose of a sulfonylurea, or 2. a fixed-dose sulfonylurea/metformin combination therapy with the same sulfonylurea and metformin requirements as for the individual components.\n* HbA1c between 7.0% and 10.0%, inclusive.\n* History of stable body weight (not varying by \\>10% for at least three months prior to screening).\n* Female patients are not breastfeeding, and female patients of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopause)\n\nExclusion Criteria:\n\n* Patients are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study.\n* Patients are employed by Lilly or Amylin.\n* Patients have participated in this study previously or any other study using AC2993 or GLP-1 analogs.\n* Patients have participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.\n* Patients have had greater than three episodes of severe hypoglycemia within 6 months prior to screening.\n* Patients are undergoing therapy for a malignancy, other than basal cell or squamous cell skin cancer.\n* Patients have cardiac disease that is Class III or IV, according to the New York Heart Association criteria.\n* Patients have a known allergy or hypersensitivity to insulin glargine, AC2993, or excipients contained in these agents.\n* Patients have characteristics contraindicating metformin or sulfonylurea use, according to product-specific label, in the opinion of the investigator.\n* Patients have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine \\>=1.5 mg/dL for males and \\>=1.3 mg/dL for females.\n* Patients have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase/serum glutamicpyruvic transaminase greater than three times the upper limit of the reference range.\n* Patients have known hemoglobinopathy or chronic anemia.\n* Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.\n* Patients have used any prescription drug to promote weight loss within 3 months prior to screening.\n* Patients have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes them from following and completing the protocol, in the opinion of the investigator.\n* Patients fail to satisfy the investigator of suitability to participate for any other reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Chief Medical Officer, MD","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Radiant Research-San Diego","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Dorothy L. and James E. Frank Diabetes Research Institute","city":"San Mateo","state":"California","zip":"94401","country":"United States","geoPoint":{"lat":37.56299,"lon":-122.32553}},{"facility":"Internal Medicine Associates Department of Research","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Baptist Diabetes Associates","city":"Miami","state":"Florida","zip":"33176","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Metabolic Research Institute, Inc.","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Springfield Diabetes & Endocrine Center","city":"Springfield","state":"Illinois","zip":"62704","country":"United States","geoPoint":{"lat":39.80172,"lon":-89.64371}},{"facility":"Frederick Primary Care Associates","city":"Frederick","state":"Maryland","zip":"21702","country":"United States","geoPoint":{"lat":39.41427,"lon":-77.41054}},{"facility":"Radiant Research, Inc.","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Lovelace Scientific Resources, Inc.","city":"Las Vegas","state":"Nevada","zip":"89102","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Diabetes, Endocrine & Nutrition","city":"Hampton","state":"New Hampshire","zip":"03842","country":"United States","geoPoint":{"lat":42.93759,"lon":-70.83894}},{"facility":"Lovelace Scientific Resources","city":"Albuquerque","state":"New Mexico","zip":"87108","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Great Lakes Medical Research","city":"Westfield","state":"New York","zip":"14787","country":"United States","geoPoint":{"lat":42.32228,"lon":-79.5781}},{"facility":"DOCS, Beth Israel Medical Center","city":"Yonkers","state":"New York","zip":"10710","country":"United States","geoPoint":{"lat":40.9304,"lon":-73.89789}},{"facility":"Piedmont Medical Research Associates","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Jon Shapiro, MD","city":"Philadelphia","state":"Pennsylvania","zip":"19146","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Endocrinology Consultants of East Tennessee","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Israel Hartman, MD","city":"Arlington","state":"Texas","zip":"76014","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Diabetes & Glandular Research Associates, P.A.","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Jack Wahlen, MD","city":"Ogden","state":"Utah","zip":"84403","country":"United States","geoPoint":{"lat":41.223,"lon":-111.97383}},{"facility":"Rainier Clinical Research Center, Inc.","city":"Renton","state":"Washington","zip":"98055","country":"United States","geoPoint":{"lat":47.48288,"lon":-122.21707}},{"facility":"Australian Clinical Research Centre","city":"Miranda","state":"New South Wales","zip":"2228","country":"Australia","geoPoint":{"lat":-34.03857,"lon":151.10005}},{"facility":"Royal North Shore Hospital","city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Clinical Trial and Research Unit","city":"Wollongong","state":"New South Wales","zip":"2500","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"Royal Brisbane Hospital","city":"Brisbane","state":"Queensland","zip":"4029","country":"Australia","geoPoint":{"lat":-27.46794,"lon":153.02809}},{"facility":"Royal Adelaid Hospital","city":"Adelaid","state":"South Australia","zip":"5000","country":"Australia"},{"facility":"Repatriation General Hospital","city":"Daw Park","state":"South Australia","zip":"5041","country":"Australia","geoPoint":{"lat":-34.98975,"lon":138.58407}},{"facility":"SA Endocrine Clinical Research","city":"Keswick","state":"South Australia","zip":"5035","country":"Australia","geoPoint":{"lat":-34.94178,"lon":138.57459}},{"facility":"Eastern Health (Box Hill Hospital)","city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Royal Melbourne Hospital","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Freemantle Hospital","city":"Freemantle","state":"Western Australia","country":"Australia"},{"facility":"UZ Antwerpen","city":"Endegem","zip":"2650","country":"Belgium"},{"facility":"UZ Gent","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"UZ Gasthuisberg","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"CHU Sart Tilman","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"A.Z. Jan Palfijn","city":"Merksem","zip":"2170","country":"Belgium","geoPoint":{"lat":51.24623,"lon":4.44903}},{"facility":"Sint Niklaasstraat","city":"Sint-Gillis-Waas","zip":"9170","country":"Belgium","geoPoint":{"lat":51.21914,"lon":4.12374}},{"facility":"Hospital Nossa Senhora das Gracas","city":"Curitiba","zip":"PR 80810-990","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Centro Integrado de Diabetes e Hipertensao","city":"Fortaleza","zip":"CE 601200-020","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Centro de Pesquisas em Diabetes e Doencas Endocrino Metabolicas/HUWC/UFC","city":"Fortaleza","zip":"CE 60430-350","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Santa Casa de Misericordia de Porto Alegre","city":"Porto Alegre","zip":"RS 90020-090","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Eiran Sairaala c/o9 Clires","city":"Helsinki","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Torikeskuksen Laakariasema, Yliopistonkatu","city":"Jyväskylä","country":"Finland","geoPoint":{"lat":62.24147,"lon":25.72088}},{"facility":"Oulu Deakoness Institution","city":"Oulu","zip":"90100","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Diabetologische Schwerpunktpraxis","city":"Aschaffenburg","zip":"63739","country":"Germany","geoPoint":{"lat":49.97704,"lon":9.15214}},{"facility":"Diabetologische Scherpunktpraxis","city":"Bosenheim","zip":"55545","country":"Germany","geoPoint":{"lat":49.84472,"lon":7.91382}},{"facility":"Diabetologische Schwerpunktpraxis","city":"Dortmund","zip":"44137","country":"Germany","geoPoint":{"lat":51.51494,"lon":7.466}},{"facility":"Krankenhaus Bethanien","city":"Hamburg","zip":"20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Universitatskliniken des Saarlandes","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"IKFE GmbH","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Profil Institut fur Stoffwechselforschung GmbH","city":"Neuss","country":"Germany","geoPoint":{"lat":51.19807,"lon":6.68504}},{"facility":"Diabetologische Schwerpunktpraxis","city":"Neuwied","zip":"56564","country":"Germany","geoPoint":{"lat":50.4336,"lon":7.47057}},{"facility":"Diabetes Centrum Bilthoven","city":"Bilthoven","zip":"3723 MB","country":"Netherlands","geoPoint":{"lat":52.13,"lon":5.20139}},{"facility":"Atrium Medisch Centrum Brunssum","city":"Brunssum","zip":"6422 BE","country":"Netherlands","geoPoint":{"lat":50.94667,"lon":5.97083}},{"facility":"Sint Antonius Ziekenhuis Nieuwegein","city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Refaja ziekenhuis","city":"Stadskanaal","zip":"9501 HE","country":"Netherlands","geoPoint":{"lat":52.98947,"lon":6.9504}},{"facility":"Medisch Centrum","city":"Westeinde","country":"Netherlands","geoPoint":{"lat":53.20853,"lon":5.76812}},{"facility":"Markeveien Spesialistpraksis","city":"Bergen","zip":"5012","country":"Norway","geoPoint":{"lat":60.39299,"lon":5.32415}},{"facility":"Spesiallegetjenesten AS","city":"Jessheim","zip":"2050","country":"Norway","geoPoint":{"lat":60.14151,"lon":11.17515}},{"facility":"Betanien Spesialistsenter","city":"Oslo","zip":"0172","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Sykehuset Asker of Baerum HF","city":"Rud","zip":"1309","country":"Norway","geoPoint":{"lat":60.43333,"lon":11.63333}},{"facility":"Forskningsstiftelsen Hjertelaget","city":"Stravanger","zip":"4011","country":"Norway"},{"facility":"Bydgoskie Centrum Diabetologii i Endokrynologii","city":"Bydgoszcz","zip":"85-822","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Oddzial Chorob Wewnetrznych","city":"Częstochowa","zip":"42-200","country":"Poland","geoPoint":{"lat":50.79646,"lon":19.12409}},{"facility":"NZOZ \"Diab-Endo-Met\"","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Poradnia Diabetologiczna","city":"Lodz","zip":"Rzgowska 281/289","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Poradnia Diabetologiczna","city":"Lublin","zip":"20-718","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Oddzial Chorob Wewnetrznych","city":"Mielec","zip":"39-300","country":"Poland","geoPoint":{"lat":50.28709,"lon":21.4239}},{"facility":"Oddzial Chorob Wewnetrznych i Diabetologii","city":"Warsaw","zip":"02-507","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Wojewodzka Poradnia dla Chorych na Cukrzyce","city":"Warsaw","zip":"03-242","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Hospital Garcia de Orta-Servico de Endocrinologia","city":"Almada","zip":"2805-267","country":"Portugal","geoPoint":{"lat":38.67902,"lon":-9.1569}},{"facility":"Centro Hospitalar de Coimbra","city":"Coimbra","zip":"3040-853","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Associacao Protectora dos Diabeticos de Portugal","city":"Lisbon","zip":"1250-203","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Hospital Geral de Santo Antonio","city":"Porto","zip":"4099-001","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Universidad Central del Caribe","city":"Bayamón","zip":"00956","country":"Puerto Rico","geoPoint":{"lat":18.39856,"lon":-66.15572}},{"facility":"Hospital Alejandro Otero Lopez","city":"Manati","zip":"00674","country":"Puerto Rico","geoPoint":{"lat":18.42745,"lon":-66.49212}},{"facility":"Dr. Luis Ruiz","city":"Ponce","zip":"00733","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"RCMI-Clinical Research Center","city":"Rio Piedras","zip":"00935","country":"Puerto Rico","geoPoint":{"lat":18.39745,"lon":-66.04989}},{"facility":"San Juan Health Center","city":"San Juan","zip":"00936-3833","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Centro de Endocrinologia del Este","city":"Yabucoa","zip":"00767","country":"Puerto Rico","geoPoint":{"lat":18.05052,"lon":-65.87933}},{"facility":"Hospital Vega Baja","city":"Alicante","zip":"03300","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Doce de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Gral de Mostoles","city":"Madrid","zip":"28934 Mostoles","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Virgen de Valme","city":"Seville","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital la Ribera, Alzira","city":"Valencia","zip":"46600 Alzira","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Lundberglaboratoriet for diabetesforskning","city":"Gothenburg","zip":"413 45","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Medicinska kliniken","city":"Helsingborg","zip":"251 87","country":"Sweden","geoPoint":{"lat":56.04673,"lon":12.69437}},{"facility":"Kliniska Forskningsenheren","city":"Lund","zip":"221 85","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Diabetesmottagningen, Intermedicinska kliniken","city":"Stockholm","zip":"118 83","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"CME, M71","city":"Stockholm","zip":"141 86","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Enheten for metabol kontroll","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}}]},"referencesModule":{"references":[{"pmid":"16230722","type":"RESULT","citation":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. doi: 10.7326/0003-4819-143-8-200510180-00006."},{"pmid":"22913891","type":"DERIVED","citation":"Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012 Jul;124(4):21-32. doi: 10.3810/pgm.2012.07.2567."},{"pmid":"22236356","type":"DERIVED","citation":"Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Two patients were lost to follow-up after receiving study drug, and it is not known if they took at least one dose of the drug. For purposes of data analysis, these patients were classified as untreated.","groups":[{"id":"FG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"FG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"283"},{"groupId":"FG001","numSubjects":"268"}]},{"type":"Received Treatment (Intent to Treat)","achievements":[{"groupId":"FG000","numSubjects":"282"},{"groupId":"FG001","numSubjects":"267"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"242"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Patient Decision","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Loss of Glucose Control","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"BG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"282"},{"groupId":"BG001","value":"267"},{"groupId":"BG002","value":"549"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.80","spread":"8.82"},{"groupId":"BG001","value":"57.96","spread":"9.46"},{"groupId":"BG002","value":"58.91","spread":"9.13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"243"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"306"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Hemoglobin (HbA1c)","description":"Change in HbA1c from baseline to week 26","populationDescription":"Last Observation Carried Forward; Intent to Treat, computed from the patients having both baseline and post baseline data","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage","timeFrame":"Baseline, week 26","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"260"}]}],"classes":[{"title":"Baseline HbA1c","categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":"0.07"},{"groupId":"OG001","value":"8.19","spread":"0.07"}]}]},{"title":"Change in HbA1c at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.06"},{"groupId":"OG001","value":"-1.05","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Pre-specified non-inferiority margin was 0.4% (i.e., noninferiority is demonstrated if the upper limit of a two-sided 95% confidence interval for the difference in change in HbA1c between exenatide and insulin glargine is less than 0.4%.)","pValue":"0.4602","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.05","ciPctValue":"95","ciLowerLimit":"-0.09","ciUpperLimit":"0.20"}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <=7%","description":"Percentage of patients in each arm who had HbA1c \\>7% at baseline and had HbA1c \\<=7% at week 26 (percentage = \\[number of subjects with HbA1c \\<=7% at week 26 divided by number of subjects with HbA1c \\>7% at baseline\\] \\* 100%).","populationDescription":"Last Observation Carried Forward; Intent to Treat","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"26 weeks","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"267"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.43"},{"groupId":"OG001","value":"48.03"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7839","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline to week 26","populationDescription":"Intent to Treat","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, week 26","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"244"}]}],"classes":[{"title":"Baseline body weight","categories":[{"measurements":[{"groupId":"OG000","value":"88.42","spread":"1.16"},{"groupId":"OG001","value":"89.25","spread":"1.20"}]}]},{"title":"Change in body weight at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-2.32","spread":"0.21"},{"groupId":"OG001","value":"1.75","spread":"0.21"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Fasting Serum Glucose","description":"Change in fasting serum glucose from baseline to week 26","populationDescription":"Last Observation Carried Forward; Intent to Treat","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, week 26","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"245"}]}],"classes":[{"title":"Baseline fasting serum glucose","categories":[{"measurements":[{"groupId":"OG000","value":"10.27","spread":"0.21"},{"groupId":"OG001","value":"10.46","spread":"0.21"}]}]},{"title":"Change in fasting serum glucose at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"0.19"},{"groupId":"OG001","value":"-2.86","spread":"0.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in 7-point Self-monitored Blood Glucose (SMBG) Profile","description":"Change in 7-point (pre-breakfast, 2 hour post breakfast, pre-lunch, 2 hour post lunch, pre-dinner, 2 hour post dinner, 0300 hours) SMBG profile from baseline to week 26","populationDescription":"Last Observation Carried Forward; Intent to Treat","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mmol/L","timeFrame":"Baseline, week 26","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"267"}]}],"classes":[{"title":"Pre-breakfast: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"9.47","spread":"0.169"},{"groupId":"OG001","value":"9.50","spread":"0.173"}]}]},{"title":"Pre-breakfast: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.130"},{"groupId":"OG001","value":"-2.56","spread":"0.132"}]}]},{"title":"2hr post breatfast: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"12.51","spread":"0.220"},{"groupId":"OG001","value":"12.36","spread":"0.226"}]}]},{"title":"2hr post breakfast: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-3.77","spread":"0.171"},{"groupId":"OG001","value":"-2.86","spread":"0.174"}]}]},{"title":"Pre-lunch: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"9.61","spread":"0.218"},{"groupId":"OG001","value":"9.47","spread":"0.224"}]}]},{"title":"Pre-lunch: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"0.156"},{"groupId":"OG001","value":"-1.93","spread":"0.158"}]}]},{"title":"2hr post lunch: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"11.15","spread":"0.222"},{"groupId":"OG001","value":"10.96","spread":"0.226"}]}]},{"title":"2hr post lunch: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.173"},{"groupId":"OG001","value":"-1.69","spread":"0.176"}]}]},{"title":"Pre-dinner: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":"0.211"},{"groupId":"OG001","value":"9.35","spread":"0.216"}]}]},{"title":"Pre-dinner: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.156"},{"groupId":"OG001","value":"-1.72","spread":"0.159"}]}]},{"title":"2hr post dinner: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"11.17","spread":"0.206"},{"groupId":"OG001","value":"11.49","spread":"0.211"}]}]},{"title":"2hr post dinner: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-3.06","spread":"0.172"},{"groupId":"OG001","value":"-1.65","spread":"0.175"}]}]},{"title":"3:00 AM: Baseline SMBG","categories":[{"measurements":[{"groupId":"OG000","value":"9.02","spread":"0.189"},{"groupId":"OG001","value":"9.36","spread":"0.192"}]}]},{"title":"3:00 AM: Change in SMBG at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"0.169"},{"groupId":"OG001","value":"-1.97","spread":"0.169"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Hypoglycemic Events","description":"Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study divided by the total number of patients who participated in the 26 week Parent Study","populationDescription":"Intent to Treat","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"26 weeks","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"267"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.32"},{"groupId":"OG001","value":"59.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3002","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Rate of Hypoglycemic Events","description":"Change in rate of hypoglycemic events per 30 days per patient from baseline to week 26","populationDescription":"Intent to Treat","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"events per 30 days per patient","timeFrame":"Baseline, week 26","groups":[{"id":"OG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)"},{"id":"OG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"267"}]}],"classes":[{"title":"Baseline event rate","categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.04"},{"groupId":"OG001","value":"0.11","spread":"0.04"}]}]},{"title":"Change in event rate at week 26","categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.06"},{"groupId":"OG001","value":"0.29","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3385","statisticalMethod":"ANCOVA","ciPctValue":"95"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Exenatide Arm","description":"Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)","seriousNumAffected":8,"otherNumAffected":226},{"id":"EG001","title":"Insulin Glargine Arm","description":"Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)","seriousNumAffected":10,"otherNumAffected":160}],"seriousEvents":[{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Angioneurotic edema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Coronary artery atherosclerosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Dermatofibrosarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Seroma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":282},{"groupId":"EG001","numAffected":1,"numAtRisk":267}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":282},{"groupId":"EG001","numAffected":0,"numAtRisk":267}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":161,"numAtRisk":282},{"groupId":"EG001","numAffected":23,"numAtRisk":267}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":282},{"groupId":"EG001","numAffected":10,"numAtRisk":267}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":282},{"groupId":"EG001","numAffected":23,"numAtRisk":267}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":282},{"groupId":"EG001","numAffected":24,"numAtRisk":267}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":282},{"groupId":"EG001","numAffected":8,"numAtRisk":267}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":282},{"groupId":"EG001","numAffected":13,"numAtRisk":267}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":282},{"groupId":"EG001","numAffected":8,"numAtRisk":267}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":282},{"groupId":"EG001","numAffected":15,"numAtRisk":267}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":282},{"groupId":"EG001","numAffected":6,"numAtRisk":267}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA7.0/11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":156,"numAtRisk":282},{"groupId":"EG001","numAffected":160,"numAtRisk":267}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Peter Ohman, Medical Science Director","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"},{"id":"D000069036","term":"Insulin Glargine"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"},{"id":"D049528","term":"Insulin, Long-Acting"},{"id":"D061385","term":"Insulins"},{"id":"D010187","term":"Pancreatic Hormones"},{"id":"D036361","term":"Peptide Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}